Understanding how cancer cells rewire their metabolism to fuel aggressive growth has become crucial for developing targeted therapies, particularly for lung cancers driven by KRAS mutations—among the most difficult to treat. This research reveals a previously unrecognized metabolic vulnerability that could transform treatment approaches for roughly 30% of non-small cell lung cancer patients.
The investigation identified ubiquitin-specific peptidase 15 (USP15) as a critical regulator enabling KRAS-mutant tumors to hijack cellular energy production. When researchers silenced USP15 expression in laboratory models, tumor cell proliferation and migration dropped dramatically, while metabolic flux assays showed severely disrupted glycolysis—the sugar-burning process cancer cells depend on for rapid growth. The enzyme operates downstream of MEK/ERK signaling, suggesting KRAS mutations specifically upregulate USP15 to sustain the metabolic demands of uncontrolled proliferation.
This finding addresses a longstanding therapeutic gap in oncology. KRAS mutations occur in approximately one-third of lung adenocarcinomas and have historically been considered "undruggable" targets. While recent KRAS inhibitors show promise, resistance frequently emerges through metabolic adaptation. USP15 represents a potentially more stable intervention point—disrupting the metabolic machinery rather than the rapidly-mutating driver itself. The enzyme's role in transcriptionally regulating glycolytic genes suggests inhibiting USP15 could starve tumors of their primary energy source. However, this remains early-stage research requiring validation in clinical trials, and the specificity of USP15 targeting to avoid disrupting normal cellular metabolism needs careful evaluation.